ALDAGEN - Leadership

www.aldagen.com

ALDAGEN's senior management has extensive experience in pharmaceutical and biotechnology product and clinical development and commercialization, business development, and financings.

W. Thomas Amick, Chairman & Chief Executive Officer
Mr. Amick has served as our Chief Executive Officer and Chairman of the Board of Directors since March 2005. Mr. Amick was retired from March 2004 until he began serving as a consultant to Aldagen in March 2005, before becoming an employee in March 2006. Mr. Amick served in a series of positions with Johnson & Johnson and its subsidiaries and divisions from 1974 until his retirement in February 2004, including Vice President, Business Development of the Johnson & Johnson Development Corporation from January 2003 to February 2004, President of Ortho Biotech Europe from June 2000 to December 2002, President of Janssen-Ortho, Inc. from March 1999 to June 2000 and Vice President of the Oncology Franchise for Ortho Biotech Products,L.P. from 1997 to March 1999. Mr. Amick has served as a director of Discovery Laboratories, Inc., a publicly traded life sciences company, since September 2004 and as the chairman of its board of directors since March 2007. Mr. Amick received a B.S. degree in business administration from Elon College.

Edward L. Field, President & Chief Operating Officer
Mr. Field has served as our President and Chief Operating Officer since November 2004. Prior to joining Aldagen, Mr. Field was the President and Chief Executive Officer of Inologic, Inc., a private biopharmaceutical company, from February 2002 to September 2004. Prior to joining Inologic, from 1999 to 2002, Mr. Field was the President of Molecumetics, Ltd., a drug discovery and development subsidiary of Tredegar Corporation, until its merger with Therics, LLC, a regenerative medicine company. Mr. Field received a Master of Business Administration degree from the University of Virginia's Darden School of Business Administration and a Bachelor of Science degree in Economics from Duke University.

Dave Carberry, Chief Financial Officer
Mr. Carberry has served as our Chief Financial Officer since March 2008. Prior to joining Aldagen, Mr. Carberry served with Johnson & Johnson and its subsidiaries and divisions in a variety of financial positions from 1981 to February 2008. Most recently, Mr. Carberry served as Vice President, Finance and Chief Financial Officer of Johnson & Johnson*Merck Consumer Pharmaceuticals Co. from March 2005 to September 2006 and as Vice President, Finance and Chief Financial Officer of Johnson & Johnson Health Care Systems Inc. from 1995 to February 2005. Concurrently, Mr. Carberry acted as Vice President, Finance and Chief Financial Officer of Independence Technology, Inc., a division of Johnson & Johnson, from September 2004 to September 2007. Mr. Carberry received a Master of Business Administration degree from Drexel University and a Bachelor of Science degree in accounting from LaSalle College. Mr. Carberry is a Certified Management Accountant.

Andrew E. Balber, Ph.D., Chief Scientific Officer
Dr. Balber is a co-founder of Aldagen and has served as our Chief Scientific Officer since 2000. Dr. Balber began his work with cell therapies in 1983 when, as a Duke University faculty member in immunology and Director of the Comprehensive Cancer Center Flow Cytometry Facility, he helped organize and manage a university-based, industry sponsored research consortium in immunology. Dr. Balber received a Bachelor of Science degree in biology from Haverford College and his Ph.D. degree from Rockefeller University and completed postdoctoral training in immunology and microbiology at Yale University.

Laurence Keller, M.D., Chief Medical Officer
Dr. Keller has served as our Chief Medical Officer since December 2007. Prior to joining Aldagen, from November 2005 to August 2007, Dr. Keller was the Senior Medical Director at Kos Pharmaceuticals, a pharmaceutical company, which was acquired by Abbott Laboratories in December 2006. Dr. Keller was previously employed by Pfizer/Parke Davis, a pharmaceutical company, where he served as Director of Clinical Research and Development from 1999 to September 2003 and as Senior Director from September 2003 to November 2005. Dr. Keller received a Bachelor of Science degree from The George Washington University and a Master of Science degree in physiology from Georgetown University. He received his M.D. degree from The George Washington University. Dr. Keller completed his internship and residency in pediatrics at The New York Hospital – Cornell Medical Center. He did his fellowship training in pediatric cardiology at St. Christopher's Hospital for Children and the Children's Hospital of Michigan. Dr. Keller also completed a postdoctoral research fellowship at the Children's Hospital of Michigan, where he studied pulmonary vascular development and angiogenesis. Dr. Keller is a board-certified pediatric cardiologist and a Fellow of the American College of Cardiology and member of the American Heart Association